Intec Pharma Ltd. (NTEC)
Symbol Info
Listed Symbol NTEC
Name Intec Pharma Ltd.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.42
Price Info
21 Day Moving Average $0.6056
21 Day EMA $0.988470
50 Day Moving Average $2.7044
50 Day EMA $2.333190
200 Day EMA $4.805770
200 Day Moving Average 5.846090
52 Week High $9.25
52 Week Low $0.41
52 Week Change $-88.642000
Alpha 0.347135
Beta -13.7162
Standard Deviation 1.851659
R2 0.073768
Periods 49
Share Information
10 Day Average Volume 1,327,272
20 Day Average Volume 3,014,998
30 Day Average Volume 2,221,453
50 Day Average Volume 1,465,479
Outstanding Shares 33,302,800
Float Shares 33,111,252
Percent Float 99.42%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 67
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 231,680
Institute Holdings Percent 38.400000
Institute Sold Previous 3 Months 1,932,223
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 6
Insider Holdings Percent 0.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 191,548
Price Change
7 Day Price Change $-0.0032
7 Day Percent Change -0.69%
21 Day Price Change $-0.02
21 Day Percent Change -4.17%
30 Day Price Change $-2.92
30 Day Percent Change -86.39%
Month To Date Price Change $-0.018
Month To Date Percent -3.77%
90 Day Price Change $-4.89
90 Day Percent Change -91.40%
Quarter To Date $-3.88
Quarter To Date Percent -89.40%
180 Day Price Change $-7.73
180 Day Percent Change -94.38%
200 Day Price Change $-7.42
200 Day Percent Change -94.16%
Year To Date $-7.08
Year To Date Percent -93.90%
Profile
Description Intec Pharma Ltd is a clinical stage biopharmaceutical company based in Israel. It is a development stage biopharmaceutical company. The company has focused its efforts on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention. Accordion Pill Carbidopa/Levodopa, or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease. The company has successfully completed a Phase II clinical trial for AP-CDLD for the treatment of Parkinson's disease symptoms.
Details
Issue Type CS
Market Cap $15,319,288
Sec Type EQS
Auditor Kesselman & Kesselman C.P.A.s
Total Shares Outstanding 33,302,800
CEO Jeffrey A. Meckler
Employees 83
Last Audit UE
Classification
CIK 0001638381
Industry Biotechnology
Sector Healthcare
NAICS
Info
Address 12 Hartom Street
Har Hotzvim
Jerusalem, 9777512
Website http://www.intecpharma.com
Facisimile
Telephone +972 25864657
Email amf@intec-us.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-5,269,438
Price To Sales -
Price To Free Cash -0.4
PE High Last 5 Years -
Price To Book 0.4
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.4
Financial Strength
Total Debt To Equity 0.0
Int Coverage 112.8
Current Ratio 2.5
Leverage Ratio 1.2
Quick Ratio 2.2
Long Term Debt To Capital 0.03
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -65.37
Return On Equity -78.04
Return On Capital -76.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
NTEC
Intec Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190819 01:59:08